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Abstract 
Background: Bipolar disorder (BD) is a chronic, frequently comorbid condition characterized by high rates of mood 
episode recurrence and suicidality. Little is known about prospective longitudinal characterization of BD type II (BD II) 
versus type I (BD I) in relation to time to depressive recurrence and recovery from major depressive episode. We there-
fore assessed times to depressive recurrence/recovery in tertiary clinic-referred BD II versus I patients.
Methods: Outpatients referred to Stanford BD Clinic during 2000–2011 were assessed with Systematic Treatment 
Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation and with Clinical Monitoring Form during 
up to 2 years of naturalistic treatment. Prevalence and clinical correlates of bipolar subtype in recovered (euthymic 
≥8 weeks) and depressed patients were assessed. Kaplan–Meier analyses assessed the relationships between bipolar 
subtype and longitudinal depressive severity, and Cox proportional hazard analyses assessed the potential mediators.
Results: BD II versus BD I was less common among 105 recovered (39.0 vs. 61.0%, p = 0.03) and more common 
among 153 depressed (61.4 vs. 38.6%, p = 0.006) patients. Among recovered patients, BD II was associated with 6/25 
(24.0%) baseline unfavorable illness characteristics/mood symptoms/psychotropics and hastened depressive recur-
rence (p = 0.015). Among depressed patients, BD II was associated with 8/25 (33.0%) baseline unfavorable illness char-
acteristics/mood symptoms/psychotropics, but only non-significantly associated with delayed depressive recovery.
Conclusions: BD II versus BD I was significantly associated with current depression and hastened depressive recur-
rence, but only non-significantly associated with delayed depressive recovery. Research on bipolar subtype relation-
ships with depressive recurrence/recovery is warranted to enhance clinical management of BD patients.
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Background
Bipolar disorder (BD) comprises a spectrum of different 
mood disorders, characterized by variable severity of ill-
ness, functional impairment, comorbidity patterns, sui-
cidal risk, cognitive impairment, and treatment response 
(Akiskal et al. 2000; Alda 2004; Duffy 2014). Within the 
bipolar spectrum, BD type II (BD II) and I (BD I) are cur-
rently the main clinically defined expressions of BD, as 
acknowledged by the fifth edition of the diagnostic and 
statistical manual of mental disorders (DSM-5) (Ameri-
can Psychiatric Association 2013).
In view of the phenomenological and biological het-
erogeneity of BDs and related clinical expressions, the 
recurrent episodic course has been traditionally consid-
ered the hallmark of the illness and the largest source 
of longitudinal burden (Angst and Sellaro 2000; Angst 
and Gamma 2008). Quality of remissions and frequency 
of recurrences are known to vary substantially between 
patients. Nevertheless, mood episode recurrences were 
found to occur in approximately half of bipolar patients 
within 2 years (Vazquez et al. 2015), and in approximately 
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three-quarters within 5 years (Gitlin et al. 1995), despite 
continuous guideline-based treatment.
Among mood episode recurrences, there is a well-
established predominance of depressive, compared with 
hypomanic/manic/mixed episodes, over the course 
of BD, with a subsequent overall greater burden in terms 
of economic costs, functioning, caregiver burden, and 
suicide (Judd et al. 2005; Di Marzo et al. 2006; Miller et al. 
2014). For instance, a Systematic Treatment Enhance-
ment Program for BD (STEP-BD) report showed that, 
among the 58% of patients who recovered from a syn-
dromal mood episode at enrollment, approximately half 
had mood episode recurrence within 2 years, with twice 
as many depressive compared to mood elevation recur-
rences (Perlis et al. 2006).
More recently, in a systematic comparison of natural-
istic studies versus randomized controlled trials, recur-
rence rates in BD were found to be substantial and 
similar, with first-episode recurrence-polarity being 
more often depressive than mood elevation (Vázquez 
et  al. 2015). In addition, depressive compared to manic 
recurrences were found to not only be more frequent and 
prolonged (Perlis et al. 2006; Tondo et al. 2016), but also 
associated with greater multi-dimensional impairment 
and symptom severity (Di Marzo et al. 2006). Therefore, 
the frequency and severity of depressive recurrences in 
BD highlight the importance to identify clinical variables 
associated with hastened depressive recurrence (i.e., 
shorter time to next major depressive episode) in order 
to devise more effective disease management strategies.
Clinical variables associated with recurrences in BD 
include younger onset age and rapid cycling (Vázquez 
et al. 2015), poor sleep quality (Cretu et al. 2016), lifetime 
comorbid anxiety disorders and current anxiety (Otto 
et al. 2006; Shah et al. 2017), seasonality (Geoffroy et al. 
2014), duration of recovery (Coryell et  al. 1995), resid-
ual symptoms (Judd et  al. 2008), subsequent treatment 
resistance, psychosocial disability, and possible func-
tional neuroanatomic changes (Goldberg et al. 2005). In 
this perspective, the role of diagnostic subtype in relation 
to recurrences and achievement of recovery in bipolar 
patients has not shown significant associations with spe-
cific variables to date, particularly with respect to time to 
depressive recurrences and recovery in BD II versus BD 
I patients. In addition, while more studies have investi-
gated recurrence rates in BD, as synthesized in a recent 
systematic review (Vázquez et  al. 2015), less is known 
about time to depressive recovery and related media-
tors (Otto et al. 2006). In both cases, moreover, potential 
differences between BD II versus BD I patients have not 
been assessed, such investigation being of relevant clini-
cal interest in order to implement specific therapeutic 
strategies in these subjects.
Aiming at assessing potential differences between 
BD subtypes, in a previous cross-sectional study by our 
group, we found in an American tertiary clinic-referred 
setting that BD II, compared to BD I patients, had illness 
that was more severe in multiple ways (e.g., more lifetime 
episodes, anxiety comorbidity, childhood onset, rapid 
cycling) but less severe in a few other ways (e.g., less hos-
pitalizations and psychosis) (Dell’Osso et  al. 2015). Fol-
lowing the above-mentioned investigation, the present 
study aimed to longitudinally assess BD subtype effects 
on time to depressive recurrence/recovery in patients 
with BD II versus BD I.
Methods
We included outpatients with BD II or BD I referred by 
community practitioners (primarily psychiatrists) to the 
Stanford University BD Clinic between 2000 and 2011. 
Patients were assessed with the Systematic Treatment 
Enhancement Program for BD (STEP-BD) Affective Dis-
orders Evaluation (Sachs et al. 2003), which included the 
Structured Clinical Interview for the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th edition (First 
et al. 1996) mood disorders module and Clinical Global 
Impression-Bipolar Version-Overall Severity (CGI-BP-
OS) score (Spearing et al. 1997). The Mini International 
Neuropsychiatric Interview (MINI) (Sheehan et al. 1998) 
was used to confirm bipolar and comorbid psychiat-
ric disorder diagnoses. Clinical status at each follow-up 
visit was determined by symptom ratings on the Clini-
cal Monitoring form (CMF) (Sachs et  al. 2002), while 
patients received measurement- and guideline-based nat-
uralistic treatment (with monthly modal visit frequency) 
for up to 2 years.
Bipolar disorder subtype (BD II vs. BD I) was deter-
mined from available medical records and patient report, 
as assessed by the STEP-BD Affective Disorders Evalu-
ation and MINI. Current mood symptoms were deter-
mined from patient report, as assessed by the STEP-BD 
Affective Disorders Evaluation at the time of enrollment, 
and clinician observation and reflected any mood symp-
toms in the 10 days prior to enrollment for the primary 
analysis, and mood symptoms thresholded for occur-
ring on at least four or seven of the 10  days prior to 
enrollment for the secondary analysis. Current psycho-
tropic medication use was based upon patient report, as 
assessed by the STEP-BD Affective Disorders Evaluation, 
and review of medical records at the time of enrollment. 
Antidepressants included Selective Serotonin Reuptake 
Inhibitors (SSRIs), Serotonin Norepinephrine Reup-
take Inhibitors (SNRIs), Atypical Antidepressants (e.g., 
bupropion, mirtazapine), and First-Generation Antide-
pressants (e.g., heterocyclic antidepressants, monoamine 
oxidase inhibitors). Mood Stabilizers included lithium, 
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valproate, carbamazepine, and lamotrigine. Antipsychot-
ics included the second-generation agents olanzapine, 
risperidone, quetiapine, aripiprazole, and ziprasidone. 
Anxiolytic/hypnotics included benzodiazepine and non-
benzodiazepine agents administered for anxiety (e.g., 
lorazepam, clonazepam, alprazolam, and buspirone) and/
or insomnia (e.g., temazepam, zolpidem, and trazodone).
As described below, clinical characteristics of partici-
pants were evaluated, and prospective clinical course of 
participants meeting diagnostic criteria for either current 
recovery (euthymic ≥8  weeks) or depression (a current 
major depressive episode) at enrollment was assessed. 
The STEP-BD protocol and the subsequent similar 
Stanford-specific Assessment, Monitoring, and Central-
ized Database protocol were approved by the Stanford 
University Administrative Panel on Human Subjects, 
and patients provided verbal and written informed con-
sent prior to participation. Trained medical and research 
staff collected data on six demographic parameters and 
25 illness characteristics/current mood symptoms/cur-
rent psychotropic medications. The demographic param-
eters assessed were (A) Age (in years); (B) Gender; (C) 
Race/Ethnicity; (D) Education; (E) Marital Status; and 
(F) Employment status. The illness characteristics/cur-
rent mood symptoms/current psychotropic medications 
assessed were (1) lifetime anxiety disorder; (2) lifetime 
alcohol/substance use disorder; (3) lifetime eating disor-
der; (4) lifetime personality disorder; (5) bipolar II dis-
order; (5A) lifetime psychosis (which is very commonly 
associated with bipolar I disorder); (5B) lifetime prior 
psychiatric hospitalization (which is also very commonly 
associated with bipolar I disorder); (6) ≥one first-degree 
relative with mood disorder; (7) onset age (in years); (8) 
Childhood (age <13 years) onset; (9) illness duration (in 
years); (10) long illness duration (≥15  years); (11) epi-
sode accumulation (≥10 prior mood episodes); (12) life-
time suicide attempt; (13) rapid cycling (≥4 episodes) in 
prior year; (14) CGI-BP-OS; current (i.e., any in the prior 
10 days) (15) sadness; (16) anhedonia; (17) euphoria; (18) 
irritability; and (19) anxiety; and current (baseline) (20) 
mood stabilizer use; (21) antipsychotic use; (22) antide-
pressant use; (23) anxiolytic/hypnotic use; (24) complex 
pharmacotherapy (≥4 mood stabilizers, antipsychotics, 
or antidepressants); and (25) number of core psychotrop-
ics (mood stabilizers, antipsychotics, or antidepressants).
Statistical analyses were performed using Statisti-
cal Package for the Social Sciences (SPSS) Version 23.0 
software (IBM Corp.; Armonk, NY, USA) on an Apple 
MacBook Air computer (Apple Corporation, Cupertino, 
CA, USA). Prevalence and clinical correlates of BD II 
versus BD I were examined in currently recovered (i.e., 
euthymic ≥8 weeks) and currently depressed (i.e., with 
a current major depressive episode) patients. Analytical 
statistics included Fisher’s Exact test comparisons of 
categorical data and independent-sample t test compari-
sons of continuous variables. In addition, binary logistic 
regression was used to adjust for potential confounding 
variables. Primary longitudinal analyses consisted of 
Kaplan–Meier survival analyses (log-rank tests), which 
compared times to depressive recurrence and recovery 
in patients with BD II versus BD I. We used the stand-
ard approaches of censoring patients with mood eleva-
tion prior to depressive recurrence in assessing time 
to depressive recurrence, and censoring patients with 
depressive prior to mood elevation recurrence in assess-
ing time to mood elevation recurrence (Tohen et  al. 
1990). Secondary metrics included for BD II versus BD 
I depressive longitudinal severity were Kaplan–Meier 
estimated recurrence/recovery rates for significant lon-
gitudinal depressive associations. Additional second-
ary analyses included Cox proportional hazard analyses 
[hazard ratios (HRs) and 95% confidence intervals (CIs)] 
for depressive recurrence and recovery, as well as for 
potential mediators of statistically significant longitudi-
nal depressive illness severity findings. To select param-
eters for entry into mediator models, univariate Cox 
proportional hazard analyses were performed for all 
statistically significant clinical correlates of bipolar sub-
type. Parameters with p < 0.05 were entered into a for-
ward stepwise procedure, and covariates were included 
in the model if p < 0.05. Additionally, Cox proportional 
hazard analyses with time-dependent covariates were 
used to further characterize statistically significant 
associations between bipolar subtype and depressive 
recurrence and recovery. To facilitate comparisons 
with prior studies, we also calculated observed and 
Kaplan–Meier estimated overall (all patients, any epi-
sode) recurrence/recovery rates. We used a two-tailed 
significance threshold with p < 0.05, with no correction 
for multiple comparisons.
Results
Table  1 includes demographics, illness characteristics, 
and current mood symptoms/psychotropic medications 
of currently recovered and currently depressed patients, 
stratified by bipolar subtype. Our sample included 153 
(30.4%) depressed and 105 (20.9%) recovered patients, 
drawn from 503 outpatients, with the remaining 245 
patients being excluded for not satisfying inclusion cri-
teria, due to lack of sustained recovery (i.e., euthymic 
<8  weeks; N  =  102, 20.3%), presence of subsyndro-
mal depression/mood elevation (i.e., >2 threshold level 
depressive or mood elevation symptoms, but NOT 
meeting DSM-IV criteria for a syndromal mood epi-
sode; N = 89, 17.7%), or syndromal mood elevation (i.e., 
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hypomanic, manic, or mixed episodes; N  =  54, 10.7%) 
clinical status.
In our sample, BD II was significantly less common in 
recovered versus depressed patients (39.0 vs. 61.4%, Chi 
square = 12.5, df = 1, p = 0.0006).
Table 1 Demographics, illness characteristics, current mood symptoms, and  current medications in  bipolar II disorder 
versus bipolar I disorder outpatients
Underline indicates parameters with statistically significant relationships with bipolar subtype; CGI-BP-OS indicates clinical global impression for bipolar disorder-
overall severity; italic font indicates parameters associated with bipolar I disorder, independent of mood state; SD indicates standard deviation
Missing data: recovered—≥10 prior episodes 12.4%, all other parameters 0.0–5.7%, depressed—≥10 prior episodes 7.2%, all other parameters 0.0–1.3%
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, bipolar II disorder versus bipolar I disorder
Recovered bipolar II Recovered bipolar I Depressed bipolar II Depressed 
bipolar I
N (%) 39.0* (41) 61.0 (64) 61.4** (94) 38.6 (59)
Demographics
A. Age (years, mean ± SD) 36.5 ± 13.8 35.8 ± 13.7 36.5 ± 13.5 35.9 ± 13.5
B. Female (%) 69.0 48.4 63.8 57.6
C. Caucasian (%) 75.0 77.4 87.2 86.4
D. College degree (%) 66.7 60.3 51.1 40.7
E. Married (current, %) 34.1 38.1 41.5 30.5
F. Full-time employment (current, %) 35.0 33.3 25.8 25.4
Comorbid disorders (lifetime, %)
1. Anxiety 61.0* 37.5 81.9 69.5
2. Alcohol/substance use 51.2 50.0 58.5 57.6
3. Eating 14.6 6.3 18.1 6.8
4. Personality 7.3 9.4 19.1* 6.8
Other illness characteristics
5. Bipolar II disorder (%) 100.0**** 0.0 100.0**** 0.0
5A. Psychosis (lifetime, %) 12.2 68.8**** 18.1 64.4****
5B. Psychiatric Hospitalization (lifetime, %) 9.8 70.3**** 6.4 57.6****
6. ≥One 1° relative with mood disorder (%) 53.7 42.2 61.7 55.9
7. Onset age (years, mean ± SD) 18.4 ± 9.0 20.1 ± 8.8 16.2 ± 8.7 18.5 ± 5.8
8. Childhood (age <13 years) Onset (%) 20.0 9.4 31.9*** 8.5
9. Illness duration (years, mean ± SD) 18.9 ± 15.4 16.4 ± 12.6 19.6 ± 13.5 17.3 ± 12.5
10. Long illness duration (≥15 years, %) 50.0 46.6 54.8 50.8
11. Episode accumulation (≥10, lifetime, %) 63.9 42.9 81.6** 56.4
12. Suicide attempt (lifetime, %) 30.8 23.8 31.2 39.0
13. Rapid cycling (prior year, %) 15.4 6.7 34.4 20.7
14. CGI-BP-OS (current, mean ± SD) 2.4 ± 0.7** 2.0 ± 0.8 5.4 ± 0.8 5.93 ± 0.7
Current mood symptoms (any in prior 10 days, %)
15. Sadness 31.7* 10.9 91.5 86.4
16. Anhedonia 22.4* 7.8 95.7 93.2
17. Euphoria 17.1 10.9 35.1* 16.9
18. Irritability 53.7** 25.0 77.7** 54.2
19. Anxiety 46.3 29.7 85.1 74.6
Medication (current)
20. Mood stabilizer (MS, %) 75.6 77.8 51.1** 75.9
21. Antipsychotic (AP, %) 31.7 40.6 20.2**** 55.9
22. Antidepressant (AD, %) 46.3* 25.0 48.9 37.3
23. Anxiolytic/hypnotic (AN, %) 24.4 23.4 31.9 40.7
24. Complex pharmacotherapy (>4 MS, AP, or AD, %) 24.4 15.6 24.5 35.6
25. Number of psychotropics (MS, AP, AD, mean ± SD) 2.6 ± 1.6 2.3 ± 1.3 2.2 ± 1.8* 2.8 ± 1.7
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Demographics and illness characteristics/current mood 
symptoms/current psychotropic medications in recovered 
patients with bipolar II disorder versus bipolar I disorder
Among recovered patients, BD II compared to BD I was 
less common (39.0 vs. 61.0%, Binomial test, p  =  0.031). 
Recovered patients with BD II versus BD I disorder had sig-
nificantly higher rates of lifetime anxiety disorder (61.0 vs. 
37.5%, Chi square = 5.5, df = 1, p = 0.027), BD II (by defini-
tion, 100.0 vs. 0.0%, Chi square = 105.0, df = 1, p < 0.0001), 
current sadness (31.7 vs. 10.9%, Chi square = 7.0, df = 1, 
p  =  0.011), anhedonia (24.4 vs. 7.8%, Chi square  =  5.6, 
df  =  1, p  =  0.023), irritability (53.7 vs. 25.0%, Chi 
square =  8.9, df =  1, p =  0.004), and antidepressant use 
(46.3 vs. 25.0%, Chi square =  5.1, df =  1, p =  0.034), as 
well as higher CGI-BP-OS (2.4 ± 0.7 vs. 2.0 ± 0.8, t = 2.9, 
df = 103, p = 0.004), but less prior psychosis (12.2 vs. 68.8%, 
Chi square = 32.1, df = 1, p < 0.0001) and prior psychiatric 
hospitalization (9.8 vs. 70.3%, Chi square =  36.8, df =  1, 
p < 0.0001), with the latter two being well-established BD II 
versus BD I differences, independent of mood state. Indeed, 
in our dataset these relationships were mediated by asso-
ciations of BD I with prior psychosis and prior psychiat-
ric hospitalization. In contrast, no assessed demographic 
parameter and no other illness characteristic/current mood 
symptom/current psychotropic medication used in Table 1 
were significantly associated with BD II versus BD I among 
recovered patients.
Demographics and illness characteristics/current mood 
symptoms/current psychotropic medications in depressed 
patients with bipolar II disorder versus bipolar I disorder
Among currently depressed patients, BD II compared to 
BD I was more common (61.4 vs. 38.6%, Binomial test, 
p  =  0.006) and was associated with more lifetime per-
sonality disorder (19.1 vs. 6.8%, Chi square = 4.5, df = 1, 
p  =  0.036), BD II (by definition, 100.0 vs. 0.0%, Chi 
square = 153.0, df = 1, p < 0.0001), childhood BD onset 
(31.9 vs. 8.5%, Chi square  =  11.3, df  =  1, p  =  0.0007), 
≥10 mood episode accumulation (81.6 vs. 56.4%, Chi 
square  =  10.6, df  =  1, p  =  0.002), and current eupho-
ria (35.1 vs. 16.9%, Chi square = 5.9, df = 1, p = 0.017) 
and irritability (77.7 vs. 54.2%, Chi square = 9.2, df = 1, 
p  =  0.0039), but less current mood stabilizer (51.1 vs. 
75.9%, Chi square = 9.2, df = 1, p = 0.0035) and antip-
sychotic (20.2 vs. 55.9%, Chi square  =  20.6, df  =  1, 
p < 0.0001) use, and fewer current psychotropic medica-
tions (2.2 ± 1.8 vs. 2.8 ± 1.7, t = 2.2, df = 151, p = 0.029), 
as well as less prior psychosis (18.1 vs. 64.4%, Chi 
square = 33.8, df = 1, p < 0.0001) and prior psychiatric 
hospitalization (6.4 vs. 57.6%, Chi square = 49.3, df = 1, 
p  <  0.0001); However, the latter two relationships were 
mediated by associations of BD I with prior psychosis and 
prior psychiatric hospitalization (Table 1). In contrast, no 
assessed demographic parameter and no other illness 
characteristic/current mood symptom/current psycho-
tropic medication used in Table 1 were significantly asso-
ciated with BD II versus BD I among depressed patients.
Bipolar subtype in relationship to time to and frequency 
of depressive recurrence
BD II versus BD I was significantly associated with has-
tened depressive recurrence (log-rank, p  =  0.015) in 41 
versus 64 recovered patients (Fig.  1). BD II versus BD I 
was also significantly associated with hastened depres-
sive recurrence using Cox proportional hazard analysis 
(HR = 2.3, 95% CI 1.2–4.6, p = 0.018). Hastened depressive 
recurrence among BD II versus BD I patients was driven 
by lifetime anxiety disorder (HR =  4.4, 95% CI 1.9–10.5, 
p = 0.001) and attenuated by lifetime history of psychosis 
(HR = 0.24, 95% CI 0.088–0.68, p = 0.007). BD II’s associa-
tion with hastened depressive recurrence was significant in 
the first year (HR = 2.3, 95% CI 1.1–4.8, p = 0.027), again 
mediated by lifetime anxiety disorder (HR =  4.4, 95% CI 
1.9–10.5, p = 0.001), and attenuated by lifetime psychosis 
history (HR = 0.24, 95% CI 0.088–0.67, p = 0.007), but not 
the second year (HR = 2.2, 95% CI 0.37–13.3, p = 0.39). BD 
II versus BD I patients had an only non-significantly higher 
(less than twice as high) 2-year Kaplan–Meier estimated 
depressive recurrence rate of 63.2% (95% CI 44.6–81.8) ver-
sus 36.2% (95% CI 20.5–51.9).
Fig. 1 Bipolar II disorder associated with hastened depressive recur-
rence. Two-year survival analysis of time to depressive recurrence in 
recovered bipolar disorder patients indicated significantly hastened 
depressive recurrence in patients with bipolar II disorder (N = 41, 
black line on bottom) versus bipolar I disorder (N = 64, gray line on top, 
log-rank, p = 0.015). Bipolar II disorder compared to bipolar I disorder 
was also significantly associated with hastened depressive recurrence 
using Cox proportional hazard analysis [hazard ratio (HR) = 2.3 (95% 
confidence interval (CI) 1.2–4.5), p = 0.018]. Lifetime anxiety disorder 
(HR = 4.4, 95% CI 1.9–10.5, p = 0.001) drove and lifetime history 
of psychosis (HR = 0.24, 95% CI 0.088–0.68, p = 0.007) attenuated 
hastened depressive recurrence in patients with bipolar II disorder 
versus bipolar I disorder
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In contrast, associations between BD II versus BD I and 
times to mood elevation recurrence (log-rank, p = 0.13, 
HR =  0.44, 95% CI 0.14–1.3, p =  0.14, in 41 versus 64 
recovered patients, not illustrated) and any mood epi-
sode recurrence (log-rank, p =  0.30, HR =  1.3, 95% CI 
0.78–2.3, p  =  0.30, in 41 versus 64 recovered patients, 
not illustrated) were non-significant. The observed and 
Kaplan–Meier estimated overall (all patients, any epi-
sode) 2-year recurrence rates were 50.5% and 65.9% (95% 
CI 54.9–76.9), respectively. As expected, the observed 
and Kaplan–Meier estimated overall (all patients, any 
episode) 1-year recurrence rates were lower at 41.0% and 
50.6% (95% CI 39.8–61.4), respectively.
Bipolar subtype in relationship to time to and frequency 
of depressive recovery
BD II versus BD I was not significantly associated with 
time to depressive recovery (log-rank, p  =  0.35) in 94 
versus 59 depressed patients (not illustrated). BD II ver-
sus BD I was also not significantly associated with time 
to depressive recovery using Cox proportional hazard 
analysis (HR = 1.2, 95% CI 0.79–1.95, p = 0.35) and was 
not significantly associated with rate of depressive recov-
ery [86.2%, 95% CI (76.2–96.2) vs. 78.4%, 95% CI (63.6–
93.2)]. In addition, BD II versus BD I was not significantly 
related to time to recovery from mood elevation epi-
sodes (log-rank, p  =  0.28) or from any mood episode 
(log-rank, p  =  0.35, not illustrated). The observed and 
Kaplan–Meier estimated overall (all patients, any epi-
sode) 2-year recovery rates were 46.4% and 84.3% (95% 
CI 76.5–92.1%), respectively. As expected, the observed 
and Kaplan–Meier estimated overall (all patients, any 
episode) 1-year recovery rates were lower at 37.2% and 
59.5% (95% CI 50.5–68.5%), respectively.
Discussion
To date and to our knowledge, the present study represents 
one of the first attempts to longitudinally assess differ-
ences in BD subtypes in relation to depressive recurrence/
recovery in BD I versus BD II patients. Results showed 
that BD II versus BD I recovered patients showed signifi-
cantly hastened depressive recurrence, driven by lifetime 
anxiety disorder and attenuated by prior psychosis. On 
the other hand, BD II versus BD I depressed patients had 
only a non-significant association with time to depressive 
recovery. Taken as a whole, our longitudinal and baseline 
comparison data, particularly in relation to the finding of 
hastened depressive recurrence in BD II patients, support, 
integrate, and extend previous reports by our and other 
groups, showing that BD II, at least in some clinical set-
tings, is not merely a milder form of illness, compared to 
BD I (Vieta et al. 1997; Judd et al. 2003a, 2005; Novick et al. 
2010; Dell’Osso et al. 2015, 2017).
Of note, findings on demographic and clinical variables 
showed that BD II versus BD I was less common among 
recovered subjects and more frequent among depressed 
patients, consistent with overall higher severity of illness, 
particularly in relation to depression proneness, for indi-
viduals with BD II versus BD I, as previously reported 
(Judd et  al. 2003a, b; Dell’Osso et  al. 2015; Faurholt-
Jepsen et al. 2015).
Thus, our findings of recovered patients with BD II ver-
sus BD I having significantly greater burden of illness, 
with approximately one-quarter of baseline demographic 
and clinical variables, are consistent with available lit-
erature showing BD II-related increases of unfavorable 
baseline characteristics/current mood symptoms/current 
psychotropics, including higher rates of anxiety disorders 
(Rihmer et  al. 2001; Henry et  al. 2003; Dell’Osso et  al. 
2017), residual symptoms (Judd et  al. 2003b) (specifi-
cally sadness, anhedonia and irritability in our sample), 
and antidepressant use (Born et al. 2009; Dell’Osso et al. 
2017) in BD II versus BD I patients.
Furthermore, our findings on demographic and clini-
cal variables in depressed patients indicating that BD II 
versus BD I patients had significantly greater problems 
with approximately one-third of baseline unfavorable 
illness characteristics/mood symptoms/psychotropics, 
including higher rates of lifetime personality disorders, 
childhood onset, >10 episode accumulation, current 
euphoria, and irritability, but less current mood stabilizer 
and antipsychotic use, and fewer current psychotropic 
medications, but less prior psychosis and psychiatric hos-
pitalizations, are consistent with prior studies (Vieta et al. 
1997; Dell’Osso et al. 2015; Yao et al. 2015).
The most noteworthy finding of the present study, 
however, is the longitudinal observation of hastened 
depressive recurrence in BD II versus BD I recovered 
individuals. This result, in fact, provides new insight 
regarding the well-established longitudinal vulnerability 
of BD II patients to depressive burden (Judd et al. 2003a, 
b; Dell’Osso et al. 2015). On one hand, our data indicate 
lifetime anxiety disorder as the mediator of hastened 
depressive recurrence in BD II versus BD I patients, 
supporting the well-established, mutual, and reciprocal 
relationship between BD and anxiety disorder comor-
bidity (Vázquez et al. 2014; Pavlova et al. 2015), with an 
additional longitudinal characterization. Of note, we 
found that hastened depressive recurrence in BD II ver-
sus BD I patients, mediated by lifetime anxiety disorder, 
was significant only in the first year of follow-up, which 
likely represents a crucial time-frame for the occurrence 
of depressive recurrences in BD II individuals, particu-
larly in those with anxious comorbidity. Indeed, a pre-
vious Canadian study found recurrences were common 
after the first manic episode with more than one-half of 
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the bipolar patients experiencing a mood event within 
12  months, although differences between patients with 
BD II and BD I were not reported (Yatham et al. 2009).
On the other hand, our findings of lower rates of base-
line prior psychosis and prior psychiatric hospitalization 
in both recovered and depressed BD II patients and of 
hastened depressive recurrence in BD II recovered indi-
viduals being attenuated by lifetime psychosis history 
further support the well-documented inverse and direct 
relationships between BD II and BD I, respectively, and 
prior psychosis and psychiatric hospitalization (Tohen 
et al. 1990).
Finally, our data on bipolar subtype in relation to time 
to and frequency of depressive recovery did not show any 
significant association, demonstrating the need for fur-
ther investigation regarding this issue.
Longitudinal analysis on time to elevation mood epi-
sode and time to recovery from mood elevation episode 
did not show any significant difference in relation to BD 
subtype, highlighting the importance to futher character-
ize and differentiate BD II from BD I not only in light of 
the manic/hypomanic symptom dimension but, particu-
larly, in terms of long-term depressive burden.
This study had noteworthy strengths and limitations. 
Strengths included assessing relationships between bipo-
lar subtype and times to not only depressive recurrence 
but also depressive recovery, using validated instruments 
to assess diagnosis and longitudinal course, and having 
substantial numbers of both recovered (N  =  105) and 
depressed (N =  153) well-characterized BD patients. In 
addition, our overall (all patients, any episode) recur-
rence/recovery rates were in broad agreement with prior 
studies (Vázquez et al. 2015; Otto et al. 2006; Perlis et al. 
2006). Moreover, our findings were not merely the result 
of depression following episodes of mood elevation, since 
cases of patients with prior recurrences of manic, hypo-
manic, and mixed episodes were censored.
However, these strengths were accompanied by limi-
tations that included the use of a sample referred to a 
suburban Northern California BD specialty clinic, limit-
ing the generalizability of our findings in our relatively 
affluent, well educated but relatively underemployed, 
predominantly female sample of BD patients with medi-
cal insurance. Additionally, our sample size, though sub-
stantial, had insufficient statistical power to be able to 
assess the overall time spent in syndromal/symptomatic/
non-symptomatic state in BD II versus I patients. Fur-
thermore, recovered status/mood episode duration prior 
to enrollment was not included in our analyses of mood 
episode recurrence/recovery. Another limitation was 
the open naturalistic treatment design, in which patients 
received diverse uncontrolled (albeit guideline-informed 
and measurement- and evidence-based) interventions. In 
particular, baseline antidepressant use was significantly 
more common in patients with BD II compared to BD I. 
However, baseline antidepressant use was not a mediator 
of hastened depressive recurrence in patients with BD II 
versus BD I in our modeling, providing a more detailed 
assessment of the nature of the contribution of baseline 
pharmacotherapy, in general, and baseline antidepres-
sant use, in particular, was beyond the scope of this study. 
Finally, we did not correct for multiple comparisons, 
which particularly limited interpretation of findings with 
p values between 0.05 and 0.01. However, this liberal sta-
tistical approach increased assay sensitivity with respect 
to our ability to detect relationships between bipolar 
subtype and baseline clinical characteristics as well as 
depressive recurrence/recovery.
Nevertheless, we contend that the association between 
BD II and hastened depressive recurrence suggests that 
BD II subtype entails an important vulnerability towards 
longitudinal depressive burden in BD. Given the large 
human and financial costs of depression in BD, further 
examination of relationships between bipolar subtype 
and depressive recurrence and recovery is warranted in 
order to enhance clinical management.
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